

- (Amended) A method of treating or inhibiting thrombosis in a subject comprising administering a composition comprising an effective amount of a PSGL-1 protein to the subject.
- (Amended) The method of claim 1, wherein the PSGL-1 protein is a soluble PSGL-1 protein or a fragment thereof, capable of treating or inhibiting thrombosis.
- A2
- 8. (Amended) The method of claim 2, wherein the soluble PSGL-1 protein comprises an extracellular domain of human PSGL-1 protein or a fragment thereof, capable of treating or inhibiting thrombosis.
- 17. (Amended) The method of claim 1, wherein the PSGL-1 protein is administered to the subject prior to thrombus formation.
- A4
- 23. (Amended) A method for increasing the movement of cells relative to blood vessels in a subject comprising administering a composition comprising an effective amount of soluble PSGL-1 protein or a fragment thereof, and allowing the PSGL-1 protein or fragment thereof to treat or inhibit thrombosis, thereby increasing the movement of cells relative to blood vessels.

As

25. (Amended) A method for inhibiting thrombus formation induced by a thrombus-inducing agent in a subject comprising administering a composition comprising an effective amount of soluble PSGL-1 protein or a fragment thereof, wherein the PSGL-1 protein or fragment is capable of treating or inhibiting thrombosis.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLL

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com